Confronting the Clinical and Economic Burden of Atopic Dermatitis:
Managed Care Considerations in an
Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Atopic Dermatitis

These are archives of live webinars held between May 11 to May 22, 2020.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from June 1, 2020 to June 1, 2022

Each session has its own specific valid dates

This series is supported by an educational grant from
Pfizer Inc.

 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Fortunately for patients with this disease, several new treatments have recently become available, and more are on the horizon, including JAK inhibitors, that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.


A Deep Dive into Emerging Therapies in the Management of Atopic Dermatitis: Managed Care Considerations on Recent Clinical Data in an Evolving Treatment Landscape

  1. Explore the unmet clinical needs in atopic dermatitis (AD) and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Review recent pathophysiological findings in AD that have informed the study of new therapeutic targets, including JAK inhibitors
  3. Examine new evidence pertaining to the safety and efficacy of new and emerging therapies in the management of AD
  4. Analyze the role of emerging JAK inhibitors in the management of AD for patients of all ages
          Physician, Nursing and CMCN credits valid to June 1, 2022

Reducing the Economic Burden of Atopic Dermatitis: What Managed Care Needs to Know to About the Changing Paradigm

  1. Explore the unmet economic needs in atopic dermatitis (AD) and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Describe approaches currently utilized by third party payers to manage costs associated with the care of patients with AD
  3. Discuss the managed care considerations of emerging therapies, including JAK inhibitors, by exploring where these agents may fit into current AD management paradigm
  4. Transform therapeutic advances and resource utilization data on emerging therapies in AD into informed health plan decisions and formulary discussions
          Physician, Nursing and CMCN credits valid to June 1, 2022

A Closer Look at the Clinical, Economic and Developmental Impact of Atopic Dermatitis: Strategies to Improve Patient Adherence, Quality of Life, Costs and Work Productivity

  1. Explore challenges to patient adherence and quality of life in atopic dermatitis (AD)
  2. Examine the economic burden of AD on patients productivity and quality of life
  3. Assess how different biomarkers, comorbidities and adherence barriers play a role in long-term treatment decision making for patients with AD
  4. Review recent clinical data around the safety of emerging JAK inhibitors currently undergoing clinical studies and their effect on patient quality of life
          Physician, Nursing and CMCN credits valid to June 1, 2022